Clicky

Ono Pharmaceutical(OPHLF)

Description: Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for treating tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for treating bronchial asthma and allergic rhinitis; and Foipan tablets for treating chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., Fate Therapeutics, Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.


Keywords: Medicine Cancer Clinical Medicine Diabetes Oncology Alzheimer's Disease Chemotherapy Parkinson's Disease Rheumatoid Arthritis Arthritis Lymphoma Asthma Hepatitis Hematology Melanoma Leukemia Osteoporosis Osteoarthritis Heart Failure Multiple Myeloma Glioblastoma Blastoma Carcinoma Hepatocellular Carcinoma Hepatitis C Syrup Nausea Peripheral Neuropathy Sepsis Anatomical Pathology Flux Lupus Allergic Rhinitis Arrhythmia Rhinitis Stoma Hodgkin Small Cell Mesothelioma I Diabetes Overactive Bladder Myeloid Leukemia Acute Leukemia Chronic Heart Failure Ii Diabetes Tomy Bronchial Asthma Chronic Myeloid Leukemia Diabetic Peripheral Neuropathy Follicular Lymphoma Malignant Pleural Mesothelioma Cachexia Chemotherapy Induced Nausea Diffuse Large B Cell Lymphoma Hematologic Cancers Intravenous Infusion Orencia Eisai Lupus Nephritis Pancreatitis Sjögren Syndrome Folli Intravenous Infusions Juvenile Idiopathic Arthritis Opdivo Central Nervous System Lymphoma Malignant Tumor Opalmon Peripheral Circulatory Disorder Pheochromocytoma Polymyositis/Dermatomyositis Positive/Negative Solid Carcinoma Proteasome Recalbon Staybla Tachyarrhythmia

Home Page: www.ono-pharma.com

8-2, Kyutaromachi 1-chome
Osaka, 541-8564
Japan
Phone: 81 6 6263 5670


Officers

Name Title
Mr. Gyo Sagara CEO, Pres & Representative Director
Mr. Shozo Matsuoka Ph.D. Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
Yukio Tani Corp. Exec. Officer & Head of Corp. Communications
Katsuji Teranishi Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.
Mr. Isao Ono Exec. Officer, Director of Corp. Research & Director
Mr. Hiroshi Ichikawa Corp. Officer & Sr. Director of Medical External Affairs
Mr. Toichi Takino Ph.D. Sr. Exec. Officer, Exec. Director of Discovery & Research and Director
Mr. Toshihiro Tsujinaka Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
Hiromu Habashita Ph.D. Corp. Officer and Deputy Exec. Director of Discovery & Research Division
Kiyoaki Idemitsu Exec. Officer, Exec. Director of Clinical Devel. & Director

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 11.5473
Trailing PE: 15.7353
Price-to-Book MRQ: 2.2859
Price-to-Sales TTM: 0.0308
IPO Date:
Fiscal Year End: March
Full Time Employees: 3687
Back to stocks